PBR Nachrichten

 

The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen's RenNano platform, in its research and development (R&D) activities focused on neuroscience therapeutics. It The post Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule appeared first on Pharmaceutical Business review....

The deal allows Novartis to exercise multiple options for exclusive global rights to develop subcutaneous versions of several of its products employing the berahyaluronidase alfa enzyme, also known The post Novartis signs deal with Alteogen for drug delivery appeared first on Pharmaceutical Business review....

The partnership aims to integrate Weave Bio's AI tools with Takeda's regulatory experience to streamline workflows within the regulatory process. The joint effort began with the use of The post Takeda and Weave Bio collaborate on AI-driven automation in drug development appeared first on Pharmaceutical Business review....

The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers. Ono Pharmaceutical The post Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology appeared first on Pharmaceutical Business review....

This marks the first FDA-approved treatment for ET in nearly 30 years. The approval is based on data from the global Phase III SURPASS ET trial, which demonstrated The post PharmaEssentia's Besremi receives FDA approval for ET appeared first on Pharmaceutical Business review....

These proceeds will support the planned and ongoing studies of Kazia's lead investigational therapy, paxalisib, in triple-negative breast cancer, hormone receptor positive/human epidermal growth factor receptor 2 negative The post Kazia closes oversubscribed offering to fund paxalisib's clinical development appeared first on Pharmaceutical Business review....

The agreement arises as part of BioXcel Therapeutics' voluntary Chapter 11 proceedings in the US Bankruptcy Court for the District of Delaware, initiating a court-supervised sale of the The post Teva Pharmaceuticals to acquire BioXcel assets for up to $125m appeared first on Pharmaceutical Business review....

The round was led by an undisclosed strategic investor. New investor RA Capital Management also participated, along with existing investors that included HanKang Capital, Qiming Venture Partners and The post AusperBio raises $120m to progress hepatitis B therapies appeared first on Pharmaceutical Business review....

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 30 April 2027. Also known as bimatoprost grenod or NCX 470, K-911 is The post FDA to review Kowa Pharmaceuticals' NDA for glaucoma eye drop K-911 appeared first on Pharmaceutical Business review....

The designation covers CMT as a whole and is not restricted to specific subtypes. The RPDD programme seeks to promote the development of therapies for rare, serious or The post FDA grants RPDD to ReviR's RTX-117 for CMT appeared first on Pharmaceutical Business review....

The therapy is indicated for children who are either new to treatment or have prior experience with antiretroviral therapies but have not been treated with integrase strand transfer The post ViiV Healthcare's Tivicay PD gains FDA approval for paediatric HIV therapy appeared first on Pharmaceutical Business review....

The regimens include Ziihera combined with Tevimbra (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy for patients with HER2+ immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridisation (ISH)+. The other The post Jazz secures FDA approval for Ziihera in advanced HER2+ GEA appeared first on Pharmaceutical Business review....

McKesson believes that the deal will support its clinical research and biopharmaceutical commercialisation services. Upon completion of the transaction, Precision Medicine Group will operate under McKesson's oncology and The post McKesson to acquire Precision Medicine Group for $2.25bn appeared first on Pharmaceutical Business review....

This regulatory status is designed for therapies targeting rare, life-threatening, or chronically debilitating diseases. Cushing's syndrome of endogenous origin is a rare endocrine disease caused in most instances The post Lundbeck's asedebart receives EC orphan designation in Cushing's syndrome appeared first on Pharmaceutical Business review....

This decision makes Orzeyful the only treatment in Japan currently indicated to address the underlying cause of narcolepsy type 1, also known as narcolepsy with cataplexy, rather than The post Takeda's Orzeyful secured Japan MHLW approval for narcolepsy type 1 appeared first on Pharmaceutical Business review....

Seralutinib is intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The private investment comprises an initial closing, a The post Gossamer Bio announces $250m in funding to advance seralutinib appeared first on Pharmaceutical Business review....

This decision provides a new therapeutic option for patients who have received at least one previous treatment. Teclistamab is a bispecific antibody administered via subcutaneous injection. It targets The post Johnson & Johnson's multiple myeloma treatment secures EC approval appeared first on Pharmaceutical Business review....

The development marks the next stage of a partnership that began in 2017 and saw further expansion in 2021. Over the last five years, more than 1,300 WellSpan The post WellSpan and Johns Hopkins renew partnership for advanced cancer care access appeared first on Pharmaceutical Business review....

Utilising its analytical platforms such as next-generation sequencing (NGS), Charles River will assist with chemistry, manufacturing, and controls (CMC) activities related to the vaccine's development. The agreement aims The post Charles River and MVC to develop enterovirus vaccine appeared first on Pharmaceutical Business review....

The approval covers both adult and paediatric patients aged eight years and above. GSDIa is a rare genetic metabolic disorder caused by a deficiency in the enzyme required The post FDA grants accelerated approval to Ultragenyx's Genglycos gene therapy appeared first on Pharmaceutical Business review....